Revenue distribution by industry:

• Food and environmental analysis: approx. 45%
• Pharmaceutical services: approx. 30%
• Diagnostics: approx. 25%

TOP 3 markets and their percentage shares:

• Europe: approx. 50%
• North America: approx. 35%
• Asia-Pacific: approx. 10%

Eurofins Scientific SE generates the majority of its revenue from food and environmental analysis, reflecting the strong demand for safety and quality in these areas. The European market is the largest, attributed to the strong presence and extensive network of laboratories in this region.

North America follows as the second largest market, driven by the growing demand for pharmaceutical services and diagnostics. The Asia-Pacific region also shows growth potential, especially through expansion into emerging markets.

Production Sites: Worldwide, with a focus on Europe and North America

Eurofins Scientific SE is a globally active company operating in bioanalytics. It operates numerous laboratories and production facilities worldwide. The focus of the production and laboratory sites is in Europe and North America, with the company also having a presence in Asia and other regions.

Eurofins is known for its extensive infrastructure, which enables it to offer a wide range of services in the areas of food, environmental, pharmaceutical, and product analytics. The global presence allows Eurofins to flexibly respond to local market requirements and offer its services worldwide.

Growth Strategy of Eurofins Scientific SE:

1. Market Expansion: Eurofins Scientific SE pursues a strategy of geographical expansion, especially in emerging markets, to strengthen its global presence.

2. Acquisitions: The company focuses on strategic acquisitions to expand its service portfolio and integrate new technologies and expertise.

3. Innovation and Technology: Eurofins continuously invests in research and development to offer innovative testing solutions and enhance its technological capabilities.

4. Digitalization: The digitalization of processes and services is a central part of the strategy to increase efficiency and improve customer solutions.

Eurofins Scientific SE focuses on a combination of organic growth and strategic acquisitions to further expand its market leadership in the field of bioanalytical services. Through investments in technology and innovation, the company aims to continuously improve its services and meet the changing needs of customers.

Main raw materials: Chemicals, laboratory consumables, technical equipment

Countries of origin: USA, Germany, China, Japan

Eurofins Scientific SE is a globally leading company in the field of bioanalytics. The company imports a variety of raw materials and materials necessary for its laboratory services. These include specialized chemicals and laboratory consumables that are sourced from various countries.

The USA and Germany are significant suppliers of high-quality chemicals and technical equipment. China and Japan also supply important laboratory consumables and technical components. These international sources enable Eurofins to offer its laboratory services at a high level of quality.

Market share: Approximately 10% in the global market for laboratory services (estimated 2025)
Research and development investments: Over 300 million euros annually (estimated 2025)
Number of laboratories worldwide: Over 900 (2025)

Eurofins Scientific SE has a significant competitive advantage due to its extensive global presence with over 900 laboratories worldwide. This broad coverage enables the company to offer a variety of services in different regions and to quickly respond to local market requirements.

Another key advantage is the high investment in research and development, amounting to over 300 million euros annually. These investments foster innovations and the development of new testing methods, helping Eurofins to differentiate itself from the competition and expand its customer base.

Additionally, Eurofins benefits from its strong market position, with an estimated market share of about 10% in the global market for laboratory services. This market leadership allows the company to leverage economies of scale and offer competitive prices, strengthening customer loyalty.

Institutional Investor Share: approximately 45% (estimated for 2025)
Insider Buys/Sells: No significant transactions in the last quarter (estimated)

Eurofins Scientific SE has traditionally had a high proportion of institutional investors, indicating confidence in the company's long-term stability and growth potential. The estimated share of around 45% reflects the interest of investment funds, pension funds, and other large institutional investors.

There were no significant insider transactions in the last quarter, suggesting that management and other insiders are currently not making significant changes to their stake in the company. This can be seen as a sign of stable confidence in the current company strategy and performance.

Market share of Eurofins Scientific SE: Estimate 10-12% (2025)

Top competitors and their market share:

1. Thermo Fisher Scientific Inc.: Estimate 15-17%
2. LabCorp (Laboratory Corporation of America Holdings): Estimate 8-10%
3. Quest Diagnostics Incorporated: Estimate 7-9%
4. SGS SA: Estimate 5-7%
5. Bureau Veritas SA: Estimate 4-6%

Eurofins Scientific SE is a leading company in the field of bioanalytics and has secured a significant market share through a wide range of services and a strong global presence. Eurofins' moat mainly consists of its extensive database, network of laboratories, and the ability to quickly respond to regulatory changes.

Compared to its competitors, Eurofins has an advantage due to its specialized expertise and the breadth of its services. Thermo Fisher Scientific, on the other hand, has a larger moat due to its comprehensive product range and strong research and development capabilities supported by its size and financial strength.

LabCorp and Quest Diagnostics also have strong market positions, especially in the USA, benefiting from established customer relationships and extensive testing capacities. SGS and Bureau Veritas are strong in the inspection and certification industry, giving them an advantage in certain segments.

Overall, Eurofins has a significant moat, but some competitors are better positioned in certain areas, intensifying the competition.

Revenue Growth: 10% (2024) Profit Growth: 8% (2024) Market Share in the Industry: 15% (2024)

Eurofins Scientific SE recorded a revenue growth of 10% and a profit growth of 8% in 2024. These growth rates indicate a solid financial performance supported by continuous expansion into new markets and the introduction of innovative services.

The company holds a market share of approximately 15% in the bioanalytical and laboratory services industry, highlighting its strong position and competitiveness. Eurofins continuously invests in research and development to expand its services and leverage technological advancements.

Additionally, Eurofins has expanded its geographical presence in recent years, further increasing the potential for future growth. Given these factors, the stock could present an attractive investment opportunity, especially for investors interested in long-term growth.

Dividend Yield: 1.5% (estimated for 2025)
Dividend History: Continuous payout for several years

Eurofins Scientific SE has regularly distributed dividends in recent years, indicating a reliable dividend policy. The dividend yield for 2025 is estimated to be around 1.5%, based on historical payouts and the company's current financial position.

The company has a solid financial foundation and diversified sources of income, which increases the likelihood of continuous dividend payments. Analysts believe that Eurofins Scientific SE will also be able to pay dividends in the future, provided that no significant economic or company-specific challenges arise.